ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Mopec Group Unveils Next-Generation Maestro Grossing Station: The Mopec Maestro Encore

News Source: Mopec

MADISON HEIGHTS, Mich., June 27, 2024 (SEND2PRESS NEWSWIRE) — Mopec Group, a leading pathology technology company and manufacturer anatomic pathology equipment & supplies, is proud to announce the launch of the Mopec Maestro Encore, the latest advancement in grossing station technology. This release marks a significant milestone in Mopec Group’s strategic effort to emphasize innovation and integration of cutting-edge digital solutions as the standard for improving pathology workflow.

Mopec Maestro Encore
Image caption: Mopec Group, a leading pathology technology company and manufacturer anatomic pathology equipment and supplies, is proud to announce the launch of the Mopec Maestro Encore, the latest advancement in grossing station technology.

The Mopec Maestro Encore now features Mopec’s state-of-the-art digital pathology solution, PathCam, as a standard inclusion in every unit. PathCam boasts automated image enhancement, seamless integration with laboratory information systems (LIS), and advanced annotation capabilities. Additionally, Mopec PathCam® is designed to for frictionless integration with the leading Electronic Health Record (EHR) system. The Encore’s hardware integration lays the groundwork for future developments in incorporating AI technology into Mopec’s digital pathology platform, further solidifying the company’s commitment to technological innovation.

“We are excited to introduce the Maestro Encore as the new benchmark in grossing station technology,” said Francis X. Dirksmeier, CEO of Mopec Group. “This product embodies our mission to empower pathology and anatomy professionals with the leading platform of products and solutions for the advancement of diagnostic accuracy, safety, research, education, and the treatment of disease.”

The Maestro Encore also features the patented SafeDraft™ Ventilation Technology, which directs air from the cutting surface’s front to the back, establishing a laminar flow pattern that enhances the effectiveness of the robust backdraft technology. This consistent ventilation is crucial in safeguarding users against potential hazardous formalin exposure.

Additionally, the new OrchestraOS introduces configurable notifications and alerts for everything from reduced airflow to filter replacements, ensuring user safety remains paramount. The easy-to-change Integrated Air Filtration System further optimizes airflow, mitigating and preventing formalin exposure risks.

“With the Maestro Encore, we are not just offering a high-quality piece of equipment; we are providing an integrated technology platform that enhances the entire pathology workflow,” said Michael McClain, Vice President of Technology at Mopec Group. “This innovation is the first step towards a future where AI technology will revolutionize anatomic pathology workflow.”

Jeff Pemberton, Vice President of Marketing & Commercial Strategy, added, “The Maestro Encore is a testament to Mopec Group’s dedication to leading the industry with innovative, technology-driven solutions that prioritize both safety and efficiency. We are proud to continue supporting pathology professionals with the tools they need to achieve excellence in their work.”

The Mopec Maestro Encore is now available for order. For more information, visit https://www.mopec.com/maestro or contact Mopec Group’s sales team.

About Mopec:

As a division of Mopec Group, Mopec is guided by our mission to empower pathology & anatomy professionals with the leading platform of products and solutions for the advancement of diagnostic accuracy, safety, research, education, and the treatment of disease. This mission has driven us to become the leading experts on anatomic and forensic pathology equipment and workflow. We’ve been working hand-in-hand with pathology professions for over 30 years developing systems and solutions that facilitate safer gross examinations.

As anatomic pathology as evolved, Mopec Group has been at the forefront, getting feedback, improving design, and solving problems. Our unwavering dedication to excellence is underscored by the widespread installations within America’s premier healthcare institutions, a testament to our continuous pursuit of providing cutting-edge tools that significantly contribute to the progress and safety of pathology and anatomy professionals worldwide. We are innovators. We are collaborators. We are grossing. Learn more: https://www.mopec.com/


This press release was issued on behalf of the news source (Mopec), who is solely responsible for its accuracy, by Send2Press Newswire.

To view the original story, visit: https://www.send2press.com/wire/mopec-group-unveils-next-generation-maestro-grossing-station-the-mopec-maestro-encore/

Copr. © 2024 Send2Press® Newswire, Calif., USA. -- REF: S2P STORY ID: 119426FCN24-3

 

INFORMATION BELOW THIS PAGE, IF ANY, IS UNRELATED TO THIS PRESS RELEASE.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.